Harvard technology to be commercialized by Vesigen Therapeutics

The startup company Vesigen will develop and commercialize the drug-delivery technology created in the lab of Harvard Chan School Professor Quan Lu.

Caroline Perry • harvard
July 22, 2020 ~10 min

Tags: science-technology harvard-th-chan-school-of-public-health office-of-technology-development quan-lu caroline-perry armms arrdc1-mediated-microvesicles blavatnik-biomedical-accesserator large-molecule-drugs vesigen-therapeutics

Clinicians may one day give up syringes in favor of pills

New formulations enable oral delivery of therapeutics traditionally delivered intravenously.

Caroline Perry • harvard
April 9, 2020 ~6 min

Tags:  engineering  basic-research  health-medicine  office-of-technology-development  i20-therapeutics

Harvard technology provides early boost to Mass. COVID testing

Aldatu Biosciences, a company born in Harvard’s labs and nurtured in its entrepreneurial ecosystem, helps the region ramp up COVID-19 testing.

Alvin Powell • harvard
March 31, 2020 ~9 min

Tags:  covid-19  coronavirus  harvard-medical-school  health-medicine  alvin-powell  office-of-technology-development  max-essex  beth-israel-deaconess-medical-center  aldatu-biosciences  christopher-rowley  david-raiser  grant-zimmerman  i-lab  iain-macleod  isaac-kohlberg  jeffrey-saffitz  pagliuca-harvard-life-lab  pandaa

Major study on Duchenne muscular dystrophy gains support

Harvard stem-cell research receives support from Sarepta Therapeutics for work on Duchenne muscular dystrophy.

Caroline Perry • harvard
Jan. 9, 2020 ~6 min

Tags:  science-technology  stem-cells  office-of-technology-development  amy-wagers  caroline-perry  duchenne-muscular-dystrophy  sarepta-therapeutics

Treatments for touch hypersensitivity explored in new research

Harvard professors David Ginty and Lauren Orefice describe how their innovations present a novel approach to treating tactile hypersensitivity in patients with autism-spectrum disorders.

Caroline Perry • harvard
Jan. 8, 2020 ~15 min

Tags:  science-technology  autism  basic-research  office-of-technology-development  david-ginty  lauren-orefice  tactile-hypersensitivity

Harvard chemists’ breakthrough advances potent anti-cancer agent

Chemists at Harvard and Eisai, a Japanese pharmaceutical company, have synthesized halichondrin, a potent anti-cancer agent found naturally in sea sponges. Because of the molecule’s “fiendishly complex” design, the feat took three decades.

Caroline Perry • harvard
June 17, 2019 ~7 min

Tags:  health-medicine  office-of-technology-development  anti-cancer  eisai  halichondrin  sea-sponge  takashi-owa  yoshito-kishi

Harvard’s immune-silent stem cell technique licensed to Sana Biotechnology

Developed through Harvard’s Blavatnik Biomedical Accelerator, an innovative immune-silent stem cell technology could lead to novel cell therapies to treat “any patient with any disease.”

Caroline Perry • harvard
March 26, 2019 ~6 min

Tags:  science-technology  office-of-technology-development  blavatnik-biomedical-accelerator  biotech  chad-cowan  department-of-stem-cell-and-regenerative-biology  isaac-t-kohlberg  otd  richard-mulligan  sana-biotechnology  steve-harr  vivian-berlin

Symposium brings spheres together to lend insights to action for elderly

A half-day conference at Harvard Business School examined the growing promise of research on aging and the potential of now-experimental interventions to one day ease the burdens of infirmity.

Alvin Powell • harvard
Feb. 6, 2019 ~10 min

Tags:  harvard-medical-school  health-medicine  alvin-powell  harvard-th-chan-school-of-public-health  aging  caremore-health  george-church  harvard-business-school  national-institute-on-aging  office-of-technology-development  richard-hodes  sachin-jain

Page 1 of 1